SCHEMBL6317613

SCHEMBL6317613

Cc1ccc(-c2noc(N)c2C(=O)NCc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
CHRM4 P08173 1/20 0.41
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
ATM Q13315 1/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 1/20 0.40
EPHX2 P34913 2/20 0.39
PPARG P37231 2/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
HDAC1 Q13547 1/20 0.39
PPARA Q07869 1/20 0.39
MAPK14 Q16539 1/20 0.39
P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323812 0.88 MLYCD (0.46) HPGDKMT2AADORA1MAPK14
SCHEMBL6322602 0.88 KMT2A (0.49) HPGDKMT2AATMMAPTADORA2A
SCHEMBL6321786 0.88 CA1 (0.51) LSSSMN1; SMN2CHRM4HPGDKMT2A
SCHEMBL6321626 0.87 ADRB2 (0.47) SMN1; SMN2HPGDMAPTEPHX2PPARG
SCHEMBL6317800 0.86 GAA (0.53) SMN1; SMN2HPGDKMT2AMAPTADORA2A
SCHEMBL6317624 0.84 HPGD (0.59) SMN1; SMN2HPGDKMT2AATMMAPT
SCHEMBL6316430 0.84 S1PR3 (0.43) CHRM4HPGDKMT2AATMADORA2A
SCHEMBL6317678 0.84 CYP1A2 (0.47) SMN1; SMN2HPGDKMT2AATMMAPT
SCHEMBL6314600 0.82 SMN1; SMN2 (0.48) SMN1; SMN2HPGDKMT2AMAPTRECQL
SCHEMBL6315399 0.82 NTRK1 (0.51) SMN1; SMN2HPGDKMT2AEPHX2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 LSS 3268/4885SMN1; SMN2 2766/4885CHRM4 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.